On August 14th, the FDA approved TB Alliance new fluorine-containing anti-tuberculosis drug Pretoman
READ MORE 2019-09-23Company News | News List
The third anti-tb drug was approved by the FDA
Holiday Notice of Mid-Autumn Festival
To all departments and all employees:According to the related provisions on national holidays &
READ MORE 2019-09-10
CPhI North America 2020 in Philadelphia USA Booth#1506
FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA,
READ MORE 2019-08-26
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib),
READ MORE 2019-08-19
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib)
READ MORE 2019-07-11
New drug delivery method, FDA approved a new epilepsy treatment
UCB announced that the USFDA has approved Nayzilam (midazolam) nasal spray for the acute treatment o
READ MORE 2019-06-28
Holiday Notice of Dragon Boat Festival
To all departments and employees:According to the related national legal & the actual situation
READ MORE 2019-05-31
Long-term anti-AIDS, Combination of two schemes submits application
On April 29, 2019，the anti-AIDS long-acting two-party “cabotegravir + Ripirilin”submitted to the FDA
READ MORE 2019-05-28
For the initial treatment of HIV patients, the FDA approved the first dual-agent combination therapy
Today, the US FDA announced that it has approved the listing of the antiviral therapy Dovato (dolute
READ MORE 2019-04-26
Novartis‘s Multiple sclerosis Innovative drug approved
Recently, US FDA announced approved the listing of Mayzent (siponimod) developed by Novartis, for th
READ MORE 2019-03-29